These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 30050494)

  • 21. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
    Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D
    J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Salivary levels of disease-related biomarkers in the early stages of Parkinson's and Alzheimer's disease:
    Sabaei M; Rahimian S; Haj Mohamad Ebrahim Ketabforoush A; Rasoolijazi H; Zamani B; Hajiakhoundi F; Soleimani M; Shahidi G; Faramarzi M
    IBRO Neurosci Rep; 2023 Jun; 14():285-292. PubMed ID: 36942319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Olfactory Impairment Is the Main Predictor of Higher Scores at REM Sleep Behavior Disorder (RBD) Screening Questionnaire in Parkinson's Disease Patients.
    Solla P; Wang Q; Frau C; Floris V; Loy F; Sechi LA; Masala C
    Brain Sci; 2023 Mar; 13(4):. PubMed ID: 37190564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma extracellular vesicle tau, β-amyloid, and α-synuclein and the progression of Parkinson's disease: a follow-up study.
    Chan L; Chung CC; Hsieh YC; Wu RM; Hong CT
    Ther Adv Neurol Disord; 2023; 16():17562864221150329. PubMed ID: 36741351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease.
    Abbasi N; Mohajer B; Abbasi S; Hasanabadi P; Abdolalizadeh A; Rajimehr R
    Mov Disord; 2018 Mar; 33(3):431-439. PubMed ID: 29436735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Associations of sleep disorders with cerebrospinal fluid α-synuclein in prodromal and early Parkinson's disease.
    Wang XT; Yu H; Liu FT; Zhang C; Ma YH; Wang J; Dong Q; Tan L; Wang H; Yu JT
    J Neurol; 2022 May; 269(5):2469-2478. PubMed ID: 34605986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of soluble TREM2 on motor progression in Parkinson's disease.
    Zhang X; Zhong X; Wang L; Li H; Yang L; Li X; Yu X; Xie A
    Neurosci Lett; 2023 Jun; 807():137277. PubMed ID: 37105353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. α-Synuclein Heterocomplexes with β-Amyloid Are Increased in Red Blood Cells of Parkinson's Disease Patients and Correlate with Disease Severity.
    Daniele S; Frosini D; Pietrobono D; Petrozzi L; Lo Gerfo A; Baldacci F; Fusi J; Giacomelli C; Siciliano G; Trincavelli ML; Franzoni F; Ceravolo R; Martini C; Bonuccelli U
    Front Mol Neurosci; 2018; 11():53. PubMed ID: 29520218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study.
    Brockmann K; Schulte C; Deuschle C; Hauser AK; Heger T; Gasser T; Maetzler W; Berg D
    Parkinsonism Relat Disord; 2015 Dec; 21(12):1427-34. PubMed ID: 26475624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease.
    Terrelonge M; Marder KS; Weintraub D; Alcalay RN
    J Mol Neurosci; 2016 Jan; 58(1):88-92. PubMed ID: 26330275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ratios of proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective study.
    Delgado-Alvarado M; Dacosta-Aguayo R; Navalpotro-Gómez I; Gago B; Gorostidi A; Jiménez-Urbieta H; Quiroga-Varela A; Ruiz-Martínez J; Bergareche A; Rodríguez-Oroz MC
    Mov Disord; 2018 Nov; 33(11):1809-1813. PubMed ID: 30423201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brain Amyloid Contribution to Cognitive Dysfunction in Early-Stage Parkinson's Disease: The PPMI Dataset.
    Fiorenzato E; Biundo R; Cecchin D; Frigo AC; Kim J; Weis L; Strafella AP; Antonini A
    J Alzheimers Dis; 2018; 66(1):229-237. PubMed ID: 30282359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.
    Alves G; Brønnick K; Aarsland D; Blennow K; Zetterberg H; Ballard C; Kurz MW; Andreasson U; Tysnes OB; Larsen JP; Mulugeta E
    J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1080-6. PubMed ID: 20547614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum Insulin-Like Growth Factor-1 in Parkinson's Disease; Study of Cerebrospinal Fluid Biomarkers and White Matter Microstructure.
    Ghazi Sherbaf F; Mohajer B; Ashraf-Ganjouei A; Mojtahed Zadeh M; Javinani A; Sanjari Moghaddam H; Shirin Shandiz M; Aarabi MH
    Front Endocrinol (Lausanne); 2018; 9():608. PubMed ID: 30450079
    [No Abstract]   [Full Text] [Related]  

  • 36. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.
    Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O
    Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Cerebrospinal Fluid Neurofilament Heavy Protein Levels With Clinical Progression in Patients With Parkinson Disease.
    Wang L; Zhang W; Liu F; Mao C; Liu CF; Cheng W; Feng J
    JAMA Netw Open; 2022 Jul; 5(7):e2223821. PubMed ID: 35881392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cerebrospinal Fluid Biomarkers in Highly Exposed PM2.5 Urbanites: The Risk of Alzheimer's and Parkinson's Diseases in Young Mexico City Residents.
    Calderón-Garcidueñas L; Avila-Ramírez J; Calderón-Garcidueñas A; González-Heredia T; Acuña-Ayala H; Chao CK; Thompson C; Ruiz-Ramos R; Cortés-González V; Martínez-Martínez L; García-Pérez MA; Reis J; Mukherjee PS; Torres-Jardón R; Lachmann I
    J Alzheimers Dis; 2016 Sep; 54(2):597-613. PubMed ID: 27567860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer's disease, mild cognitive impairment, or healthy controls: a two year follow-up study.
    Berge G; Sando SB; Albrektsen G; Lauridsen C; Møller I; Grøntvedt GR; Bråthen G; White LR
    BMC Neurol; 2016 Sep; 16(1):180. PubMed ID: 27653987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease.
    Pagano G; De Micco R; Yousaf T; Wilson H; Chandra A; Politis M
    Neurology; 2018 Sep; 91(10):e894-e905. PubMed ID: 30089615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.